Frequently Asked Questions (FAQs)

What are the possible costs?

The authority may retain actuaries, accountants, attorneys or other professionals who are qualified and have expertise in the type of transaction under review as necessary to assist the authority in conducting its review of the proposed transaction.

The parties submitting the information for a proposed transaction shall pay the authority reasonable cost and expenses incurred by the authority in the performance of the authority’s duties pursuant to the Health Care Consolidation Oversight Act for cost associated with the authority’s contracts with experts, unless determined otherwise by the secretary.

There may be administrative fines incurred for transactions that are effectuated prior to approval by the Health Care Authority. These fines range from $5,000 per instance of violation to a maximum of $15,000 per day.  Money collected from these fines will be deposited to the state treasury to credit of the current school fund as provided in Article 12, Section 4 of the constitution of New Mexico.

There are also Whistleblower fines ranging from $10,000 per violation and not to exceed $100,000 per violation.

DivisionDivision of Health Improvement (DHI)
ProgramHealth Care Consolidation Oversight Act
What happens if entering into Agreement and Effectuation of Agreement?

Entry into a binding agreement before a transaction is effectuated is not a violation of the Health Care Consolidation Act if the transaction remains subject to regulatory review and approval. 

The parties shall not effectuate a transaction without the written approval of the secretary. 

The submitting party shall notify the authority in a form and manner prescribed by the authority when a transition is effectuated.  Once notified, the process for licensing or ownership change will be followed as mandated by the state.

DivisionDivision of Health Improvement (DHI)
ProgramHealth Care Consolidation Oversight Act
Is long-acting injectable MAT covered under JUST Health Plus?

Long-acting injectable MAT (e.g., Buprenorphine) is covered by Medicaid and therefore reimbursable under JUST Health Plus. All MAT drugs are preferred regardless of brand. Please refer to the Preferred Drug List (PDL).

DivisionMedical Assistance Division (MAD)
ProgramJustice-involved Utilization of State Transitioned Healthcare (JUST Health)
What is the expectation for MAT medications in-hand upon release?

MAT medications, up to a 30-day supply, must be provided in-hand upon release as clinically appropriate. HCA expects prescribers to use their clinical judgement when determining the appropriate amount of medication to provide upon release. The provision of long-acting injectable MAT prior to release may fulfill the requirement for the (up to) 30-day supply of medications upon release.

DivisionMedical Assistance Division (MAD)
ProgramJustice-involved Utilization of State Transitioned Healthcare (JUST Health)
Is diagnosis and initiation of HepC treatment required or only maintenance of existing HepC treatment?

JUST Health Plus covers initiation and maintenance of HepC treatment under Service Level 2. Providing maintenance of HepC treatment is allowable under the 1115 demonstration (JUST Health Plus) as facilities ramp-up treatment capacity, but the goal is to test and treat HepC as clinically appropriate. Facilities are expected to offer treatment when testing for HepC (as clinically indicated).

DivisionMedical Assistance Division (MAD)
ProgramJustice-involved Utilization of State Transitioned Healthcare (JUST Health)